Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 3: Hypertrophic Cardiomyopathy, Arrhythmogenic Right Ventricular Cardiomyopathy and Other Cardiomyopathies, and Myocarditis: A Scientific Statement From the American Heart Association and American College of Cardiology
Barry J. Maron, James E. Udelson, Robert O. Bonow, Rick A. Nishimura, Michael J. Ackerman, N.A. Mark Estes III, Leslie T. Cooper, Jr, Mark S. Link, Martin S. Maron, and on behalf of the American Heart Association Electrocardiography and Arrhythmias Committee of the Council on Clinical Cardiology, Council on Cardiovascular Disease in the Young, Council on Cardiovascular and Stroke Nursing, Council on Functional Genomics and Translational Biology, and the American College of Cardiology
Circulation. 2015; published online before print November 2 2015, doi:10.1161/CIR.0000000000000239
The American Heart Association and American College of Cardiology have released a series of scientific statements regarding eligibility and disqualification recommendation for competitive athletes with cardiovascular abnormalities. This is the 4th document of 15 scientific statements. “Hypertrophic cardiomyopathy (HCM) is a major focus of this document given that it is the single most common cause of sudden death.” The document includes recommendations throughout.
View 81 other recent position statements, consensus statements, guidelines, and recommendations related to sports medicine.